Search this site

ChatEHR: Innovative AI software developed by Stanford Medicine enables Clinicians to ask questions directly of Patient records ChatEHR developed by Stanford Medicine ChatEHR is an innovative AI-powered software developed by Stanford Medicine to streamline clinical workflows and enhance patient care. Designed to integrate seamlessly with electronic health record (EHR) systems, ChatEHR allows clinicians to interact with patient data using natural language queries, significantly reducing the time and effort required for chart reviews and other administrative tasks. By leveraging advanced artificial intelligence, the tool enables healthcare providers to ask questions directly of patient records—such as retrieving specific medical histories, lab results, or treatment plans—and receive accurate, contextually relevant responses in real time. The primary goal of ChatEHR is to improve efficiency, reduce clinician burnout, and enhance decision-making by making EHR interactions more intuitive and less cumbersome. It addresses the challenges of navigating complex medical records, which often require extensive manual searching. For example, a clinician can ask, “What are the patient’s most recent lab results?” or “Has this patient been prescribed any new medications in the last six months?” and ChatEHR will extract and summarise the relevant information instantly. Developed under Stanford Medicine’s focus on advancing healthcare through technology, ChatEHR reflects a commitment to human centred AI solutions that prioritise patient outcomes and clinician well-being. The tool is part of broader efforts at Stanford to integrate AI into healthcare responsibly, ensuring accuracy, security, and compliance with medical regulations. Source: https://med.stanford.edu/news/all-news/2025/06/chatehr.html ChatEHR: A Brief History of Stanford Medicine's AI-Powered Clinical Tool ChatEHR is an innovative artificial intelligence (AI)-backed software developed by Stanford Medicine, designed to revolutionise clinical workflows and enhance patient care by allowing clinicians to interact with patient medical records through a conversational interface. The genesis of ChatEHR can be traced back to 2023. A team of Stanford Medicine researchers, notably led by Dr. Shah and Anurang Revri, Vice President and Chief Enterprise Architect for Stanford Health Care's Technology and Digital Services, recognized the immense potential of large language models (LLMs) in transforming healthcare. This realisation served as the inspiration to embark on the development of what would become ChatEHR. Currently, ChatEHR is in a pilot stage at Stanford Health Care. Its core functionality enables clinicians to pose questions about a patient's medical history, automatically summarize lengthy charts, and execute other vital tasks, thereby streamlining information retrieval and improving efficiency within the clinical environment. The software leverages information directly from individual health records to generate its responses, aiming to provide a seamless and intuitive way for healthcare providers to access and utilise patient data. Future potential use cases of ChatEHR Stanford Medicine's ChatEHR, currently in its pilot phase, represents a significant step towards leveraging AI in clinical settings. Its future potential use cases are vast and align with broader trends in AI-driven healthcare innovation: 1. Enhanced Clinical Decision Support and Diagnostics: Proactive Risk Prediction: Moving beyond current capabilities, ChatEHR could analyze real-time patient data and historical records to predict a patient's risk of deteriorating health, developing specific conditions (like sepsis or peripheral artery disease), or readmission, allowing for earlier interventions. Augmented Diagnostic Capabilities: While not replacing human diagnosticians, ChatEHR could integrate with imaging analysis (e.g., cardiac MRI, X-rays), lab results, and genomic data to offer more comprehensive and precise diagnostic insights, potentially even identifying subtle patterns missed by human observation. Evidence Based Treatment Recommendations: The system could evolve to not only summarize patient histories but also synthesise vast amounts of medical literature and guidelines to offer personalised, evidence-based treatment recommendations tailored to an individual patient's characteristics, including lifestyle, medication history, and genetic makeup. 2. Streamlined Administrative and Clinical Workflows Automated Documentation and Note Generation: Expanding on its current ability to draft responses to patient emails, ChatEHR could significantly reduce the administrative burden on clinicians by automatically generating comprehensive clinical notes, discharge summaries, and even referral letters based on ambient voice recognition during patient encounters. Optimised Resource Allocation: By analysing patient flow, bed availability, and staff schedules, ChatEHR could assist in optimising resource allocation within hospitals and clinics, potentially even suggesting appropriate patient transfers between care units. Pre-Visit Data Collection and Intake: AI chatbots integrated with ChatEHR could autonomously collect pre-visit information such as reasons for visits, medication usage, allergies, and symptoms, automatically populating EHR fields and saving clinicians valuable time during appointments. 3. Enhanced Patient Engagement and Personalized Care 24/7 Patient Interaction and Support: ChatEHR could serve as a continuous point of contact for patients, handling tasks like appointment scheduling, medication reminders, answering insurance questions, and triaging non-urgent symptoms, thereby improving patient access and satisfaction. Personalised Health Coaching and Monitoring: For chronic disease management (e.g., diabetes, hypertension), ChatEHR could prompt patients for daily readings, provide personalised lifestyle coaching, and alert providers if readings fall outside normal ranges. Culturally Competent Care: Future iterations could incorporate AI models trained to understand and respond to diverse cultural nuances, potentially even assisting in creating culturally sensitive care plans or dietary recommendations. 4. Global Health Applications and Bridging Access Gaps Expanding Access in Low-Resource Settings: Stanford Medicine is already exploring how generative AI can bridge healthcare gaps in low- and middle-income countries. ChatEHR could be instrumental in providing personalised and reliable healthcare information to patients in areas with limited access to medical professionals or specialised care. Multilingual Support: Future developments could include robust multilingual natural language processing (NLP) capabilities, breaking down language barriers and making healthcare information accessible to a wider global population, including support for regional dialects. 5. Advanced Data Utilisation and Research Population Health Management: By leveraging aggregated, anonymised patient data, ChatEHR could contribute to identifying at-risk populations and developing proactive public health interventions. Accelerated Research and Discovery: The ability to swiftly synthesise vast datasets from EHRs could accelerate biomedical research by identifying patterns, correlations, and potential insights for new treatments or disease understanding. Patient Digital Twins: Combining real-time chat data, EHR history, and wearable device data, ChatEHR could contribute to creating "digital twins" of patients, enabling more precise and predictive medicine. As AI technology continues to advance, particularly in areas like responsible AI development and ethical considerations, ChatEHR is poised to play an increasingly central role in shaping the future of human-centred healthcare. Nelson Advisors > Healthcare Technology M&A . Nelson Advisors specialise in mergers, acquisitions  &  partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions &  partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today !   https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025 Nelson Advisors specialise in mergers, acquisitions  &  partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.

Kaiser Permanente's 7 Principles of Responsible AI in Healthcare Kaiser Permanente has outlined seven principles for the responsible use of artificial intelligence (AI) in healthcare to ensure safe, equitable, and effective implementation. These principles, as described by Dr. Daniel Yang, Vice President of AI and Emerging Technologies at Kaiser Permanente, are designed to prioritize patient safety, trust, and clinical excellence while aligning with the organization's mission to deliver high-quality, affordable care. Below are the seven principles: Transparency : Kaiser Permanente emphasises clear communication about how AI systems are used and the rationale behind AI-driven decisions. This includes informing patients and clinicians about AI’s role in care to foster trust and ensure understanding. Accountability : Healthcare providers and AI developers must take responsibility for the outcomes of AI applications, particularly when errors occur. This principle ensures that AI systems are held to high ethical standards and that there is clear ownership of results. Safety : AI tools must be rigorously evaluated for safety before deployment. Kaiser Permanente conducts thorough quality assurance processes to ensure tools like the Abridge clinical documentation system are safe and reliable, protecting patients from potential harm. Equity : AI systems are designed to deliver equitable, evidence-based care. Kaiser Permanente leverages its diverse membership and comprehensive datasets to develop and test AI tools, ensuring they do not perpetuate biases or disparities in healthcare outcomes. Quality : AI tools must align with Kaiser Permanente’s mission to deliver high-quality care. This involves evaluating tools for accuracy and effectiveness, ensuring they enhance clinical outcomes and patient experiences, as seen in programs like the Advance Alert Monitor, which saves an estimated 500 lives annually. Privacy : Patient data privacy is a priority. AI tools must comply with state and federal privacy laws, encrypt data, and obtain patient consent before use. For example, Kaiser Permanente ensures patients can opt out of AI-driven tools like Abridge if they choose. Clinician Oversight : AI must augment, not replace, the judgment of clinicians. Kaiser Permanente requires doctors and clinicians to review and edit AI-generated outputs, such as clinical notes, to ensure human expertise remains central to medical decision-making. These principles guide Kaiser Permanente’s approach to AI deployment, as demonstrated in initiatives like the Advance Alert Monitor, which uses predictive analytics to prevent patient deterioration, and the Abridge tool, which reduces administrative burdens for clinicians. The organization also advocates for policymakers to establish national AI oversight frameworks and industry-specific standards to support responsible AI use across healthcare. Kaiser Permanente Kaiser Permanente, a leading American integrated managed care consortium, has a rich history rooted in a pioneering approach to healthcare delivery. Its origins trace back to the vision of industrialist Henry J. Kaiser and physician Dr. Sidney R. Garfield. Here 's a timeline of key milestones: 1930s: Early Seeds of Prepaid Care 1933: Dr. Sidney Garfield opened the Contractors General Hospital near Desert Center, California, to provide care for workers building the Los Angeles Aqueduct. Facing financial challenges with a fee-for-service model, Garfield developed a prepaid healthcare plan where insurance companies paid a set amount in advance for each worker covered. This laid the groundwork for the future model. 1938: Intrigued by Garfield's approach, Henry J. Kaiser persuaded him to set up a similar prepaid practice for workers building the Grand Coulee Dam in Washington state. This plan expanded to include workers' families, emphasising preventive care and early treatment. 1940s: World War II Expansion and Public Opening 1942: With America's entry into World War II, Henry Kaiser established health plans for his burgeoning workforce at shipyards in Richmond, California, and Vancouver, Washington, and a steel mill in Fontana, California. Dr. Garfield was instrumental in organizing these large-scale care programs for thousands of workers, including many women, disabled individuals, and people of color, ensuring equitable treatment. The Permanente Foundation was established in California to support these efforts. July 21, 1945: Following World War II and a decline in shipyard workers, Kaiser Permanente officially opened its membership to the public. The Permanente Health Plan was formed as a non-profit trust. 1948: The first Permanente Medical Group was formed in Northern California, establishing the physician-led group practice model. 1950s-Present: Growth, Integration, and Innovation 1952: The health plans and hospitals changed their name from Permanente to Kaiser to leverage Kaiser Industries' national recognition, while the physician groups retained the Permanente name, thus creating the well-known "Kaiser Permanente." Mid-1950s: A critical agreement between Kaiser management and the Permanente Medical Groups solidified a unique partnership, allowing for healthy growth and a self-sustained, non-profit prepaid group medical practice. Subsequent Decades: Kaiser Permanente expanded its regional coverage, grew its membership significantly, and became a major integrated healthcare organization. It continued to emphasize preventive care, evidence-based medicine, and integrated services, including hospitals, medical offices, and comprehensive medical groups. Innovation: Kaiser Permanente has been a pioneer in various areas, including medical research, the adoption of technology (like electronic medical records in the 1970s), and a commitment to diversity and inclusion. In 2020, they opened the Kaiser Permanente Bernard J. Tyson School of Medicine. Today, Kaiser Permanente remains a significant force in the healthcare landscape, serving millions of members across several states and the District of Columbia, maintaining its core principles of integrated, affordable, and high-quality care. Kaiser Permanente history of using AI in healthcare Kaiser Permanente has a notable history of embracing technological advancements, and its journey with Artificial Intelligence (AI) in healthcare is a continuation of this commitment to innovation, particularly in leveraging its extensive integrated data. While the widespread public focus on generative AI is more recent, Kaiser Permanente has been exploring and deploying AI and machine learning (ML) applications for several years. Here's a look at their history of using AI in healthcare: 1) Early Adopters of Data-Driven Approaches: Even before the term "AI" became ubiquitous in healthcare, Kaiser Permanente, with its vast and comprehensive electronic health record (EHR) system and diverse member base, was uniquely positioned to leverage large datasets for improving patient care. This data-driven approach naturally paved the way for the adoption of more sophisticated machine learning and AI technologies. Key Milestones and Applications: Predictive Analytics and Early Warning Systems (Mid-2010s onwards): One of Kaiser Permanente's most significant and well-documented early AI applications is the Advanced Alert Monitor (AAM) program. This AI tool, which has been in use for several years (at least since 2019, according to some reports), analyzes hospital patients' electronic health data hourly to predict those at high risk for serious clinical decline or adverse events (like impending ICU admission or unexpected death). The AAM system sends alerts to specialised virtual quality nursing teams, allowing for timely intervention and preventing hundreds of deaths annually (reported to be around 500 lives per year). This demonstrates their early adoption of predictive analytics in a live clinical setting with tangible outcomes. Their research in this area, including studies published in journals like the Journal of the American Medical Informatics Association (JAMIA) , dates back to at least 2019, where they used machine learning to understand the complexity of sepsis and identify patient subgroups for more tailored treatment. Augmented Intelligence in Medicine and Healthcare Initiative (AIM-HI) (Launched by 2023): Recognising the growing potential and complexity of AI, Kaiser Permanente established the AIM-HI Coordinating Center. This initiative, housed within the Kaiser Permanente Northern California Division of Research (DOR), focuses on rigorously evaluating the implementation of AI and ML algorithms in real-world healthcare settings. AIM-HI awards grants to other healthcare organisations to conduct research projects, demonstrating Kaiser Permanente's commitment not only to its own AI adoption but also to advancing the responsible use of AI across the broader healthcare ecosystem. This shows a strategic, collaborative approach to AI innovation. Leveraging AI for Imaging and Diagnostics: Kaiser Permanente has explored and implemented AI systems in radiology, such as computer vision tools that can analyse mammograms to identify high-risk cancers that might be invisible to the human eye. This highlights their use of AI for enhanced diagnostic capabilities. Recent Focus on Generative AI (Late 2023 - 2024): In late 2023, Kaiser Permanente created the role of Vice President of Artificial Intelligence and Emerging Technologies, hiring Dr. Daniel Yang to lead their AI strategy. This signifies a significant organisational commitment to scaling AI. A major recent development has been their large-scale rollout of generative AI-powered clinical documentation tools (ambient scribes) in collaboration with companies like Abridge. This technology listens to patient-physician conversations (with consent) and drafts clinical notes for the EHR, aiming to reduce physician burnout by cutting administrative tasks. This initiative, which began with pilots in 2024 and expanded nationally, is considered one of the largest deployments of generative AI in healthcare to date. Early analyses have shown significant reductions in after-hours documentation time and improved physician satisfaction, along with better patient-physician communication. 2) Emphasis on Responsible AI: Throughout their AI journey, Kaiser Permanente has consistently emphasized a "responsible AI" framework. This involves rigorous evaluation of AI tools for quality, safety, effectiveness, accuracy, and equity before deployment. They also prioritize patient privacy, data security, transparency, and continuous monitoring of AI tool performance to ensure beneficial patient outcomes. Their "7 Principles of Responsible AI in Healthcare" formalise this commitment. In essence, Kaiser Permanente's history with AI is characterised by a pragmatic and patient centred approach, leveraging its integrated system and vast data resources to develop and implement AI solutions that improve care delivery, enhance efficiency, and support clinicians, all while maintaining a strong focus on ethical considerations and responsible deployment Nelson Advisors > Healthcare Technology M&A . Nelson Advisors specialise in mergers, acquisitions  &  partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions &  partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today !   https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025 Nelson Advisors specialise in mergers, acquisitions  &  partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America

National Institute for Health and Care Excellence poised to play a bigger role in UK HealthTech and feature as a central theme in the new NHS 10 Year Plan NICE to play a leading role in the new NHS 10 Year Plan The National Institute for Health and Care Excellence (NICE) is indeed positioned to take on a significantly expanded role in shaping the UK HealthTech landscape, a development that is expected to be a central feature of the widely anticipated new NHS 10 Year Plan. Recent announcements and consultations from NICE itself underscore this strategic shift, aiming to accelerate the adoption of innovative, cost-effective technologies across the health service. At the core of this expanded role are NICE's ongoing proposals to fundamentally transform its HealthTech programme. Announced in February 2025, these reforms represent the "biggest shake-up" of NICE's approach to health technology evaluation to date. The changes are designed to streamline the assessment process for a broad spectrum of innovations, including medical devices, diagnostics, and critically, the burgeoning fields of digital health and Artificial Intelligence (AI) technologies. One of the most significant proposed changes is the move away from requiring medical devices to demonstrate cost-savings for recommendation. Instead, independent committees will assess all technologies based on a more holistic view of their cost-effectiveness, balancing the financial outlay with the benefits they bring to patients and the wider health service. This shift is intended to open the door for a wider range of beneficial innovations that might not offer immediate cost reductions but deliver substantial improvements in patient outcomes or system efficiencies. Furthermore, NICE plans to merge its three existing evaluation programmes (interventional procedures, medical technologies evaluation, and diagnostics assessment) into a single, unified HealthTech programme. This consolidation, coupled with the introduction of a "lifecycle evaluation approach," will allow NICE to assess technologies at various stages of their development – from early-stage promising innovations to those already in routine use. The aim is to provide clearer, quicker, and more targeted guidance that directly aligns with NHS priorities. Multi-technology assessments of similar products will also become standard, helping the NHS make more informed purchasing decisions where multiple options exist. This evolution of NICE's role is intrinsically linked to the strategic direction of the NHS as outlined in the "new NHS 10 Year Plan" (or the "Change NHS" initiative). The plan explicitly emphasizes a transformative shift from an "analogue to digital" health service, from "hospital to community" care, and from "treatment to prevention." HealthTech, and robust data management for precision medicine, are seen as crucial enablers for these changes. By fast-tracking the evaluation and adoption of clinically and cost-effective technologies, NICE will directly support the NHS's ambition to improve productivity, enhance patient experience through digital solutions, and ensure the health service is fit for the future. The potential for NICE to play a bigger role also extends to fostering greater collaboration and transparency across the UK HealthTech ecosystem. By offering more tailored support to developers early in the product lifecycle and setting clear evidence standards, NICE can reduce uncertainty for industry, encourage investment in UK-aligned innovations, and ultimately get cutting-edge tools into the hands of healthcare professionals and patients faster. This forward-looking stance positions NICE as a pivotal enabler of innovation, crucial for the UK to harness the full potential of HealthTech in delivering a more personalised, efficient, and sustainable healthcare system. 10 reasons why NICE should play a bigger role in Healthcare Technology across the NHS 10 reasons why NICE should play a bigger role in Healthcare Technology across the NHS The National Institute for Health and Care Excellence (NICE) plays a crucial role in the UK's healthcare landscape, primarily through its evidence-based guidance on health and social care. However, as healthcare technology rapidly evolves, there are compelling reasons why NICE should expand its influence and responsibilities, particularly in the realm of new and emerging technologies. There are compelling reasons why the National Institute for Health and Care Excellence (NICE) should expand its role in the assessment and integration of healthcare technology within the UK. Here are 10 key reasons: Ensuring Value for Money and Efficient Resource Allocation: With increasing pressure on NHS budgets, NICE's rigorous, evidence-based appraisal process is crucial for ensuring that new technologies offer genuine clinical benefit and are cost-effective. A larger role would help prevent the widespread adoption of technologies that offer marginal gains at disproportionate costs, thereby optimising resource allocation across the NHS. Driving Innovation and Early Adoption of Beneficial Technologies: A more proactive NICE could help identify and fast-track the adoption of truly innovative and transformative healthcare technologies. By engaging earlier in the development pipeline and providing clear pathways for assessment, NICE could incentivise companies to develop solutions tailored to NHS needs and facilitate quicker patient access to effective new tools. Standardising Quality and Safety Across the NHS: A stronger NICE influence would lead to greater consistency in the quality and safety standards of healthcare technologies adopted across different NHS trusts. This would reduce regional variations in care, ensuring that all patients in the UK have access to technologies that have met a high bar for efficacy and safety. Providing Clarity and Confidence for Developers and Investors: A clear and expanded role for NICE would offer greater predictability and transparency for healthcare technology developers and investors. Knowing the assessment criteria and pathways upfront would reduce uncertainty, encourage investment in the UK market, and help companies design products that are more likely to meet NHS requirements. Addressing the Challenges of Digital Health and AI: The rapid proliferation of digital health solutions, AI-powered diagnostics, and machine learning tools presents unique challenges for evaluation. NICE's expertise in evidence synthesis and health economics is vital to develop appropriate methodologies for assessing these complex technologies, ensuring their safe and effective integration into clinical practice. Informing Commissioning Decisions: NICE's appraisals provide invaluable guidance for Clinical Commissioning Groups (CCGs) and integrated care systems (ICSs) in making informed decisions about which technologies to commission. A broader remit would mean more comprehensive guidance, leading to better strategic planning and investment in technology at a local level. Building Public Trust and Confidence: The public needs assurance that the healthcare technologies used within the NHS are effective, safe, and represent good value. NICE's independent and transparent appraisal process instills confidence, and a larger role would further reinforce public trust in the adoption of new medical innovations. Facilitating Real-World Evidence Generation: NICE is well-placed to drive the systematic collection and utilization of real-world evidence (RWE) for healthcare technologies post-market. A stronger role could involve setting standards for RWE collection, collaborating with industry to establish data capture mechanisms, and using this data to refine existing guidance and inform future appraisals. Influencing International Standards and Collaboration: As a globally respected institution, an expanded role for NICE in healthcare technology assessment would further solidify the UK's position as a leader in this field. This could foster greater international collaboration in developing best practices for technology evaluation and potentially streamline processes for technologies entering multiple markets. Adapting to the Evolving Healthcare Landscape: The healthcare landscape is continually evolving with new technologies, treatment paradigms, and patient expectations. NICE, with its established framework and adaptability, is ideally positioned to evolve its role to meet these challenges, ensuring that the UK healthcare system remains at the forefront of technological advancement while safeguarding patient interests. By empowering NICE to play a more significant role, the UK can ensure a more strategic, efficient, and patient-centric approach to the adoption of healthcare technology, ultimately leading to better outcomes for patients and a more sustainable NHS. Nelson Advisors > Healthcare Technology M&A . Nelson Advisors specialise in mergers, acquisitions  &  partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions &  partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today !   https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025 HIMSS AI in Healthcare > 10-11th July 2025 Nelson Advisors specialise in mergers, acquisitions  &  partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.

Genomic Data Management for Precision Medicine: HealthTech market to watch in 2025 Genomic Data Management in Precision Medicine The HealthTech market for Genomic Data Management in Precision Medicine is poised for significant growth in 2025, driven by the increasing demand for personalized healthcare and advancements in genomic technologies. The global precision medicine market, which heavily relies on genomic data, is projected to grow from $191.31 billion in 2024 to $207.80 billion by 2032, with a CAGR of 10.8%. This growth is fuelled by the rising prevalence of chronic diseases, such as cancer and cardiovascular conditions, where genomics plays a pivotal role in tailoring treatments. Genomic data management is critical for precision medicine, as it involves handling vast, heterogeneous datasets from sources like Next-Generation Sequencing (NGS). These datasets are often spread across multiple repositories, in various formats, and require robust systems to ensure quality and usability. The integration of big data analytics, artificial intelligence (AI), and machine learning is transforming this space by enabling faster analysis and interpretation of genomic data, which is essential for identifying disease-specific biomarkers and developing targeted therapies. A key trend in 2025 is the adoption of cloud-native genomic workflows, which are becoming a competitive edge for R&D and data science teams in precision medicine. These platforms address challenges like large file sizes, incompatible formats, and siloed teams, which have historically slowed progress. Additionally, the market is seeing increased investment in pharmacogenomics data integration platforms, which are expected to grow at an 18% CAGR, driven by the need to harmonise genetic, clinical, and pharmaceutical data for personalised treatment strategies. North America dominates the market, holding a 53.62% share in 2023, due to strong government support and advancements in genomic research. However, Asia Pacific is expected to grow rapidly, with initiatives like the Genome Asia 100K project aiming to sequence 100,000 Asian genomes to enhance population-specific precision medicine. Despite the promise, challenges remain, including the high cost of genomic testing infrastructure and the complexity of integrating genomic data into electronic health records (EHRs), which often lack compatibility with genetic data formats. Genomic Data Management for Precision Medicine market The Genomic Data Management for Precision Medicine market in 2025 is driven by companies leveraging advanced technologies like Next-Generation Sequencing (NGS), AI, and cloud-based platforms to manage and analyse vast genomic datasets. Here are some leading players in the US, UK, and Europe: United States: Illumina, Inc.: A global leader in genomic sequencing, Illumina provides NGS solutions and tools like the TruSight Oncology Comprehensive kit, widely used for comprehensive genomic profiling in precision medicine. They dominate the market with their sequencing technology, essential for personalized therapies. Thermo Fisher Scientific, Inc.: Known for its Clinical Next-Generation Sequencing and Oncology segment, Thermo Fisher collaborates with entities like Genomics England to advance liquid biopsies for cancer, enhancing genomic data applications in precision medicine. Tempus: This company uses AI and machine learning to analyze clinical and molecular data, offering solutions that integrate genomic data into personalized treatment strategies, particularly in oncology. United Kingdom: Genomics England: A national asset, Genomics England collaborates with the NHS to integrate whole-genome sequencing into routine care. Their partnership with IQVIA has created a Real-World research platform, connecting clinical and genomic data to advance precision medicine research. Congenica: Specialising in clinical genome analysis, Congenica’s Sapientia platform uses machine learning to produce diagnostic reports from genomic data, supporting precision medicine applications in hospitals across the UK and Europe. Eagle Genomics: A key player in genomic data management, Eagle Genomics focuses on bioinformatics solutions, helping pharmaceutical companies and research institutions manage and interpret genomic data for precision medicine. Europe: Qiagen (Germany): Qiagen is a major player in molecular testing, with a Centre of Excellence in Manchester, UK, for companion diagnostics in precision medicine. Their QIAseq xHYB portfolio supports comprehensive genomic profiling, and they’re expanding in the NGS market. Sophia Genetics (Switzerland): This company applies AI to genomic data, offering a platform that analyzes DNA sequences to identify mutations for diseases like cancer, improving diagnostic accuracy in precision medicine. Eurofins Genomics (Part of Eurofins Scientific Group, Luxembourg): A significant player in the NGS market, Eurofins provides genomic sequencing technologies to over 20,000 customers worldwide, supporting precision medicine through large-scale genomic data management. These companies are at the forefront of integrating genomic data into precision medicine, addressing challenges like data complexity and interoperability while driving innovation in personalized healthcare. However, the high costs of genomic testing and data storage remain hurdles, particularly in Europe, where adoption lags behind the US due to funding and infrastructure gaps. Nelson Advisors > Healthcare Technology M&A . Nelson Advisors specialise in mergers, acquisitions  &  partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions &  partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today !   https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025 Nelson Advisors specialise in mergers, acquisitions  &  partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America

Exec Summary Patient engagement and patient portals are expected to play an increasingly important role in healthcare by 2030. As healthcare becomes more consumer-centric, patients are demanding more control over their own health and wellness. Patient portals provide them with a convenient and secure way to access their medical records, communicate with their healthcare providers, and manage their care. Here are some of the key trends expected to shape patient engagement and patient portals by 2030: Increased adoption of patient portals: By 2030, it is expected that the majority of patients will have access to a patient portal. This will be driven by a number of factors, including the increasing availability of high-speed internet, the growing popularity of mobile devices, and the government's efforts to promote the use of health information technology (HIT). Promoting preventive care and population health: Patient portals can be used to promote preventive care and population health. For example, patients can use their portals to receive reminders for vaccinations and screenings. Public health officials can also use patient portals to send targeted messages to patients about important health issues. Supporting value-based care: Patient portals can be used to support value-based care by providing patients with information about their costs of care and quality ratings for healthcare providers. This can help patients to make more informed decisions about their care and choose providers that deliver high-quality care at a reasonable cost. More personalised and engaging patient portals: Patient portals in 2030 will be more personalised and engaging than they are today. They will use artificial intelligence (AI) and machine learning to tailor the patient experience to individual needs. For example, patients may be able to receive personalized health recommendations, reminders, and alerts based on their medical history, risk factors, and lifestyle goals. Integration with other healthcare technologies: Patient portals in 2030 will be more integrated with other healthcare technologies, such as wearable devices and remote monitoring systems. This will allow patients to share their health data with their healthcare providers more easily and seamlessly. For example, a patient with diabetes may be able to use their wearable device to track their blood sugar levels and automatically send the data to their doctor's portal. Greater use of patient portals for care coordination: Patient portals in 2030 will be used more extensively for care coordination. This means that patients will be able to use their portals to schedule appointments, request prescription refills, and communicate with all of the members of their healthcare team, including specialists, nurses, and pharmacists. Community engagement: Patients are more likely to stay engaged in their healthcare when they feel connected to a community of other patients who are going through similar experiences. Healthcare providers are likely to invest in tools and programs that foster patient communities and support patient engagement. Focus on wellness: As the healthcare industry continues to shift towards a more holistic view of health, patient engagement is likely to focus more on wellness and prevention, rather than just treating illness. Healthcare providers may offer more education and resources to help patients maintain a healthy lifestyle and prevent chronic conditions. Overall, patient engagement and patient portals are expected to play a vital role in the future of healthcare. By giving patients more control over their own health and wellness, patient portals can help to improve the quality and efficiency of care. Nelson Advisors > Healthcare Technology M&A . Nelson Advisors specialise in mergers, acquisitions  &  partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions &  partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today !   https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025 What exactly is patient engagement? Patient engagement refers to the active involvement of patients in their own healthcare. It involves a partnership between patients and healthcare providers, with patients taking an active role in decisions about their care and treatment. Patient engagement can take many different forms, including: Education: Providing patients with information about their health condition, treatment options, and self-management strategies can help to empower them to take an active role in their own care. Communication: Encouraging open communication between patients and healthcare providers can help to build trust and improve the quality of care. This can involve listening to patient concerns, answering questions, and providing feedback. Shared decision-making: Working with patients to make decisions about their own care, based on their individual preferences and values, can help to improve patient satisfaction and adherence to treatment plans. Self-management: Providing patients with the tools and resources they need to manage their own health, such as mobile apps or patient portals, can help to improve patient outcomes and reduce the burden on the healthcare system. Patient-centered care: Focusing on the needs and preferences of the patient, rather than the needs of the healthcare system, can help to improve patient satisfaction and outcomes. Overall, patient engagement is a key component of high-quality healthcare. It involves empowering patients to take an active role in their own care, and working collaboratively with healthcare providers to make decisions about treatment and management of health conditions. What is the future of patient portals? The future of patient portals is likely to involve increased integration with other healthcare technologies, more personalized features, and greater emphasis on patient engagement and communication. One trend that is likely to continue is the integration of patient portals with electronic health record (EHR) systems. This will allow patients to access their medical records, test results, and other health information more easily, and enable healthcare providers to share information more effectively. In addition, patient portals are likely to become more personalized and tailored to individual patients' needs. For example, patients may be able to access customized care plans and educational materials based on their health conditions or personal preferences. They may also be able to communicate with their healthcare providers more easily through secure messaging and telemedicine features. Another trend in patient portals is the use of artificial intelligence (AI) and machine learning (ML) to improve patient care. These technologies can help providers identify patterns in patient data, predict health outcomes, and provide more personalized treatment recommendations. Finally, patient portals are likely to continue to evolve in response to changing patient needs and preferences. For example, younger patients may prefer mobile apps that allow them to access their health information and communicate with their providers on-the-go, while older patients may prefer more traditional web-based portals. Overall, the future of patient portals is likely to involve a greater emphasis on patient engagement, more seamless integration with other healthcare technologies, and continued innovation in response to evolving patient needs and preferences. What are the advantages of hospital patient portals? Hospital patient portals have several advantages, both for patients and healthcare providers. Here are some of the key benefits: Improved patient engagement: Patient portals allow patients to access their health information, test results, and medical history from anywhere with an internet connection. This can help patients take a more active role in their own healthcare and improve their overall health outcomes. Increased efficiency: Patient portals can streamline administrative tasks, such as scheduling appointments, refilling prescriptions, and filling out forms. This can save time for both patients and healthcare providers, and reduce the risk of errors or delays. Enhanced communication: Patient portals can provide a secure platform for patients to communicate with their healthcare providers. Patients can ask questions, request appointments, and receive updates on their care without having to make phone calls or visit the hospital in person. Better patient outcomes: Studies have shown that patients who use patient portals are more likely to adhere to their treatment plans, have better chronic disease management, and experience improved health outcomes overall. Reduced healthcare costs: Patient portals can reduce healthcare costs by minimizing the need for in-person visits and administrative tasks. This can also improve access to care for patients who may have difficulty traveling to the hospital or taking time off work. Overall, hospital patient portals can improve patient engagement, increase efficiency, enhance communication, improve patient outcomes, and reduce healthcare costs. What are the disadvantages of hospital patient portals? While hospital patient portals offer many advantages, there are also some potential disadvantages to consider. Here are a few examples: Limited access: Some patients may not have access to the internet or may not be comfortable using digital technologies, which could limit their ability to use patient portals effectively. Security concerns: Patient portals contain sensitive health information, which could be vulnerable to data breaches or unauthorized access. It's important for hospitals to implement strong security measures to protect patient information. User experience: Patients may find some patient portals difficult to use or navigate, which could discourage them from using the portal or lead to frustration. Incomplete information: While patient portals can provide patients with access to their health information, there may be gaps in the information available or errors in the data. Patients may need to rely on their healthcare providers to fill in these gaps or correct errors. Dependence on technology: Patient portals rely on technology, which can sometimes fail or be unavailable. This could limit patients' ability to access their health information or communicate with their healthcare providers. It's important to note that many of these disadvantages can be mitigated through proper training, education, and implementation of patient portals. Hospitals can also work to address these concerns by listening to patient feedback and continuously improving their patient portal systems. What are the clinical benefits of patient engagement? Patient engagement can have several clinical benefits, both for individual patients and the healthcare system as a whole. Here are some examples: Improved health outcomes: When patients are engaged in their own care, they are more likely to adhere to treatment plans, take medications as prescribed, and make positive lifestyle changes. This can lead to improved health outcomes, such as better management of chronic conditions and reduced risk of complications. Increased patient satisfaction: When patients feel more involved in their own care, they are more likely to be satisfied with their healthcare experience. This can improve patient loyalty and retention, and lead to better patient-provider relationships. Better communication: Patient engagement can improve communication between patients and healthcare providers, making it easier to share information and make decisions about treatment. This can lead to more effective care and better health outcomes. Increased patient safety: Patient engagement can help to identify potential safety issues or errors before they become serious problems. Patients who are engaged in their own care are more likely to notice changes in their symptoms or medication side effects, and to report them to their healthcare providers. More efficient use of healthcare resources: When patients are engaged in their own care, they are less likely to require emergency room visits or hospitalizations. This can reduce the strain on the healthcare system and lead to cost savings for both patients and providers. Overall, patient engagement can lead to improved health outcomes, increased patient satisfaction, better communication, increased patient safety, and more efficient use of healthcare resources. What is the future of patient engagement? The future of patient engagement is likely to involve a greater emphasis on digital technologies, personalized care, and proactive communication. Here are some of the key trends to watch for: Digital engagement: As patients become more comfortable with digital technologies, healthcare providers are likely to continue to invest in digital engagement tools, such as patient portals, telemedicine, and mobile health apps. These technologies can make it easier for patients to access health information, communicate with their healthcare providers, and manage their own health. Personalised care: Patients are increasingly looking for personalised care that takes into account their individual needs, preferences, and health goals. Healthcare providers are likely to respond by developing more customized care plans and treatment recommendations, leveraging technologies such as machine learning and artificial intelligence to analyze patient data and provide more personalized care. Proactive communication: Rather than waiting for patients to reach out when they have a problem or need assistance, healthcare providers are likely to become more proactive in their communication with patients. This could involve regular check-ins, automated reminders, and other forms of outreach designed to keep patients engaged and informed. Community engagement: Patients are more likely to stay engaged in their healthcare when they feel connected to a community of other patients who are going through similar experiences. Healthcare providers are likely to invest in tools and programs that foster patient communities and support patient engagement. Focus on wellness: As the healthcare industry continues to shift towards a more holistic view of health, patient engagement is likely to focus more on wellness and prevention, rather than just treating illness. Healthcare providers may offer more education and resources to help patients maintain a healthy lifestyle and prevent chronic conditions. Overall, the future of patient engagement is likely to involve a greater focus on digital tools, personalised care, proactive communication, community engagement, and wellness. Final Thoughts Patient portals have the potential to make a significant impact on the healthcare system in the next 10 years. Here are some of the biggest ways they could do this: Improved patient engagement: Patient portals can help patients become more engaged in their own care. By providing easy access to medical information and allowing patients to communicate directly with their providers, patient portals can empower patients to take a more active role in their health. Increased efficiency: Patient portals can help providers and staff be more efficient. By automating tasks such as scheduling appointments and sending reminders, patient portals can free up providers and staff to spend more time with patients. Reduced costs: Patient portals can help reduce healthcare costs. By allowing patients to access their medical information online and communicate with their providers electronically, patient portals can help reduce the need for office visits and phone calls. Improved quality of care: Patient portals can help improve the quality of care. By providing patients with access to their medical information, patient portals can help patients better understand their conditions and treatment plans. This can lead to better adherence to medication regimens and other treatment recommendations. In addition to these general benefits, patient portals can also have a specific impact on different areas of healthcare. For example, patient portals can be used to: Manage chronic diseases: Patient portals can help patients manage chronic diseases such as diabetes, heart disease, and asthma. By providing patients with access to their lab results, medication history, and educational resources, patient portals can help patients stay on track with their treatment plans and improve their overall health. Coordinate care: Patient portals can help coordinate care for patients with multiple providers. By providing all of the patient's medical information in one place, patient portals can make it easier for providers to communicate with each other and ensure that the patient is receiving the best possible care. Support telemedicine: Patient portals can be used to support telemedicine, which is the delivery of healthcare services remotely. By allowing patients to communicate with their providers and access their medical information online, patient portals can make it possible for patients to receive care without having to travel to a doctor's office or hospital. Overall, patient portals have the potential to make a significant impact on the healthcare system in the next 10 years. By improving patient engagement, increasing efficiency, reducing costs, and improving the quality of care, patient portals can help make healthcare more accessible and affordable for everyone. Nelson Advisors > Healthcare Technology M&A . Nelson Advisors specialise in mergers, acquisitions  &  partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions &  partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today !   https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025

What exactly is patient engagement? Patient engagement refers to the active involvement of patients in their own healthcare. It involves a partnership between patients and healthcare providers, with patients taking an active role in decisions about their care and treatment. Patient engagement can take many different forms, including: Education: Providing patients with information about their health condition, treatment options, and self-management strategies can help to empower them to take an active role in their own care. Communication: Encouraging open communication between patients and healthcare providers can help to build trust and improve the quality of care. This can involve listening to patient concerns, answering questions, and providing feedback. Shared decision-making: Working with patients to make decisions about their own care, based on their individual preferences and values, can help to improve patient satisfaction and adherence to treatment plans. Self-management: Providing patients with the tools and resources they need to manage their own health, such as mobile apps or patient portals, can help to improve patient outcomes and reduce the burden on the healthcare system. Patient-centred care: Focusing on the needs and preferences of the patient, rather than the needs of the healthcare system, can help to improve patient satisfaction and outcomes. Overall, patient engagement is a key component of high-quality healthcare. It involves empowering patients to take an active role in their own care, and working collaboratively with healthcare providers to make decisions about treatment and management of health conditions. What is the future of patient portals? The future of patient portals is likely to involve increased integration with other healthcare technologies, more personalized features, and greater emphasis on patient engagement and communication. One trend that is likely to continue is the integration of patient portals with electronic health record (EHR) systems. This will allow patients to access their medical records, test results, and other health information more easily, and enable healthcare providers to share information more effectively. In addition, patient portals are likely to become more personalized and tailored to individual patients' needs. For example, patients may be able to access customized care plans and educational materials based on their health conditions or personal preferences. They may also be able to communicate with their healthcare providers more easily through secure messaging and telemedicine features. Another trend in patient portals is the use of artificial intelligence (AI) and machine learning (ML) to improve patient care. These technologies can help providers identify patterns in patient data, predict health outcomes, and provide more personalized treatment recommendations. Finally, patient portals are likely to continue to evolve in response to changing patient needs and preferences. For example, younger patients may prefer mobile apps that allow them to access their health information and communicate with their providers on-the-go, while older patients may prefer more traditional web-based portals. Overall, the future of patient portals is likely to involve a greater emphasis on patient engagement, more seamless integration with other healthcare technologies, and continued innovation in response to evolving patient needs and preferences. What are the advantages of hospital patient portals? Hospital patient portals have several advantages, both for patients and healthcare providers. Here are some of the key benefits: Improved patient engagement: Patient portals allow patients to access their health information, test results, and medical history from anywhere with an internet connection. This can help patients take a more active role in their own healthcare and improve their overall health outcomes. Increased efficiency: Patient portals can streamline administrative tasks, such as scheduling appointments, refilling prescriptions, and filling out forms. This can save time for both patients and healthcare providers, and reduce the risk of errors or delays. Enhanced communication: Patient portals can provide a secure platform for patients to communicate with their healthcare providers. Patients can ask questions, request appointments, and receive updates on their care without having to make phone calls or visit the hospital in person. Better patient outcomes: Studies have shown that patients who use patient portals are more likely to adhere to their treatment plans, have better chronic disease management, and experience improved health outcomes overall. Reduced healthcare costs: Patient portals can reduce healthcare costs by minimizing the need for in-person visits and administrative tasks. This can also improve access to care for patients who may have difficulty traveling to the hospital or taking time off work. Overall, hospital patient portals can improve patient engagement, increase efficiency, enhance communication, improve patient outcomes, and reduce healthcare costs. What are the disadvantages of hospital patient portals? While hospital patient portals offer many advantages, there are also some potential disadvantages to consider. Here are a few examples: Limited access: Some patients may not have access to the internet or may not be comfortable using digital technologies, which could limit their ability to use patient portals effectively. Security concerns: Patient portals contain sensitive health information, which could be vulnerable to data breaches or unauthorised access. It's important for hospitals to implement strong security measures to protect patient information. User experience: Patients may find some patient portals difficult to use or navigate, which could discourage them from using the portal or lead to frustration. Incomplete information: While patient portals can provide patients with access to their health information, there may be gaps in the information available or errors in the data. Patients may need to rely on their healthcare providers to fill in these gaps or correct errors. Dependence on technology: Patient portals rely on technology, which can sometimes fail or be unavailable. This could limit patients' ability to access their health information or communicate with their healthcare providers. It's important to note that many of these disadvantages can be mitigated through proper training, education, and implementation of patient portals. Hospitals can also work to address these concerns by listening to patient feedback and continuously improving their patient portal systems. What are the clinical benefits of patient engagement? Patient engagement can have several clinical benefits, both for individual patients and the healthcare system as a whole. Here are some examples: Improved health outcomes: When patients are engaged in their own care, they are more likely to adhere to treatment plans, take medications as prescribed, and make positive lifestyle changes. This can lead to improved health outcomes, such as better management of chronic conditions and reduced risk of complications. Increased patient satisfaction: When patients feel more involved in their own care, they are more likely to be satisfied with their healthcare experience. This can improve patient loyalty and retention, and lead to better patient-provider relationships. Better communication: Patient engagement can improve communication between patients and healthcare providers, making it easier to share information and make decisions about treatment. This can lead to more effective care and better health outcomes. Increased patient safety: Patient engagement can help to identify potential safety issues or errors before they become serious problems. Patients who are engaged in their own care are more likely to notice changes in their symptoms or medication side effects, and to report them to their healthcare providers. More efficient use of healthcare resources: When patients are engaged in their own care, they are less likely to require emergency room visits or hospitalizations. This can reduce the strain on the healthcare system and lead to cost savings for both patients and providers. Overall, patient engagement can lead to improved health outcomes, increased patient satisfaction, better communication, increased patient safety, and more efficient use of healthcare resources. What is the future of patient engagement? The future of patient engagement is likely to involve a greater emphasis on digital technologies, personalized care, and proactive communication. Here are some of the key trends to watch for: Digital engagement: As patients become more comfortable with digital technologies, healthcare providers are likely to continue to invest in digital engagement tools, such as patient portals, telemedicine, and mobile health apps. These technologies can make it easier for patients to access health information, communicate with their healthcare providers, and manage their own health. Personalised care: Patients are increasingly looking for personalized care that takes into account their individual needs, preferences, and health goals. Healthcare providers are likely to respond by developing more customised care plans and treatment recommendations, leveraging technologies such as machine learning and artificial intelligence to analyse patient data and provide more personalised care. Proactive communication: Rather than waiting for patients to reach out when they have a problem or need assistance, healthcare providers are likely to become more proactive in their communication with patients. This could involve regular check-ins, automated reminders, and other forms of outreach designed to keep patients engaged and informed. Community engagement: Patients are more likely to stay engaged in their healthcare when they feel connected to a community of other patients who are going through similar experiences. Healthcare providers are likely to invest in tools and programs that foster patient communities and support patient engagement. Focus on wellness: As the healthcare industry continues to shift towards a more holistic view of health, patient engagement is likely to focus more on wellness and prevention, rather than just treating illness. Healthcare providers may offer more education and resources to help patients maintain a healthy lifestyle and prevent chronic conditions. Overall, the future of patient engagement is likely to involve a greater focus on digital tools, personalized care, proactive communication, community engagement, and wellness. Nelson Advisors > Healthcare Technology M&A . Nelson Advisors specialise in mergers, acquisitions  &  partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions &  partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today !   https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025

Exec Summary: The average revenue multiple for HealthTech companies in 2023 is 4.5x. This is down from 6.5x in 2022, but still higher than the average revenue multiple for all technology companies, which is 3.5x. The higher revenue multiple for HealthTech companies reflects the fact that the healthcare market is growing rapidly and there is a lot of demand for innovative digital health solutions. The average revenue multiples for different types of HealthTech companies in 2023 are: Telehealth companies: 5.5x Wellness companies: 4.0x Drug discovery companies: 7.0x Medical device companies: 5.0x Healthcare IT companies: 3.5x. Factors influencing the average revenue multiple for HealthTech companies today are: The growth of the healthcare market. The adoption of digital health solutions by healthcare providers. The development of new and innovative digital health applications. The level of competition in the HealthTech sector. The overall economic climate. 10 Key Variables in HealthTech M&A valuation multiples today are: Stage of the company's development: Early-stage companies are typically valued at a lower multiple than more mature companies. Size of the company: Larger companies are typically valued at a higher multiple than smaller companies. Intellectual property portfolio: Companies with valuable intellectual property are typically valued at a higher multiple. Quality of the management team: A strong management team can add value to a company and may lead to a higher valuation. Revenue growth: This is one of the most important factors in determining the valuation of a healthtech company. Companies with strong revenue growth are typically valued at a premium to those with slower growth. Gross margin: Gross margin is a measure of a company's profitability. Companies with higher gross margins are typically valued at a premium to those with lower margins. Customer acquisition costs: Customer acquisition costs (CAC) are the costs associated with acquiring new customers. Companies with lower CACs are typically valued at a premium to those with higher CACs. Market share: Market share is a measure of a company's dominance in its industry. Companies with a large market share are typically valued at a premium to those with a smaller market share. Regulatory landscape: The regulatory landscape for healthtech is constantly evolving. Companies that operate in industries with a favourable regulatory environment are typically valued at a premium to those that operate in industries with a more challenging regulatory environment. Technology moat: A technology moat is a competitive advantage that makes it difficult for other companies to compete with a company. Companies with a strong technology moat are typically valued at a premium to those that do not have a moat. Nelson Advisors > Healthcare Technology M&A . Nelson Advisors specialise in mergers, acquisitions  &  partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions &  partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today !   https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025 HealthTech M&A valuation multiples HealthTech M&A valuation multiples are a set of metrics used to determine the value of a HealthTech company in an acquisition or merger. These multiples are typically based on financial metrics such as revenue, earnings, or users/subscribers, and can differ based on the company's stage of development, growth prospects, market position, and other relevant factors. Some of the most commonly used HealthTech M&A valuation multiples include: Enterprise value (EV) to sales: This multiple is the most common way to value healthtech companies. It is calculated by dividing the company's enterprise value (EV) by its trailing 12-month revenue. EV to EBITDA: This multiple is used to measure a company's profitability. It is calculated by dividing the company's EV by its earnings before interest, taxes, depreciation, and amortization (EBITDA). Price to earnings (P/E) ratio: This multiple is used to measure a company's valuation relative to its earnings. It is calculated by dividing the company's stock price by its earnings per share (EPS). Price to sales (P/S) ratio: This multiple is used to measure a company's valuation relative to its sales. It is calculated by dividing the company's stock price by its trailing 12-month revenue. The specific multiple that is used to value a HealthTech company will depend on a number of factors, including the company's stage of development, growth prospects, market position, and other relevant factors. However, the multiples listed above are a good starting point for understanding how HealthTech companies are valued in M&A transactions. It is important to note that valuation multiples are just one factor that is considered when valuing a healthtech company. Other factors, such as the company's management team, its intellectual property, and its strategic positioning, can also play a role in determining the company's valuation. Here are some of the recent trends in HealthTech M&A valuation multiples: Valuation multiples vary depending on the sub-sector of healthtech. For example, companies in the telehealth sector typically command higher valuation multiples than companies in the medical device sector. Valuation multiples are also affected by the stage of development of the company. Companies that are still in the early stages of development typically command lower valuation multiples than companies that are more mature. Valuation multiples have been increasing in recent years. This is due to a number of factors, including the growing demand for digital health solutions, the increasing investment in healthtech by venture capitalists, and the favorable regulatory environment for healthtech companies. Current HealthTech M&A valuation multiples In terms of valuation, the 10 Key Variables in HealthTech M&A valuation multiples today are: Stage of the company's development: Early-stage companies are typically valued at a lower multiple than more mature companies. Size of the company: Larger companies are typically valued at a higher multiple than smaller companies. Intellectual property portfolio: Companies with valuable intellectual property are typically valued at a higher multiple. Quality of the management team: A strong management team can add value to a company and may lead to a higher valuation. Revenue growth: This is one of the most important factors in determining the valuation of a healthtech company. Companies with strong revenue growth are typically valued at a premium to those with slower growth. Gross margin: Gross margin is a measure of a company's profitability. Companies with higher gross margins are typically valued at a premium to those with lower margins. Customer acquisition costs: Customer acquisition costs (CAC) are the costs associated with acquiring new customers. Companies with lower CACs are typically valued at a premium to those with higher CACs. Market share: Market share is a measure of a company's dominance in its industry. Companies with a large market share are typically valued at a premium to those with a smaller market share. Regulatory landscape: The regulatory landscape for healthtech is constantly evolving. Companies that operate in industries with a favourable regulatory environment are typically valued at a premium to those that operate in industries with a more challenging regulatory environment. Technology moat: A technology moat is a competitive advantage that makes it difficult for other companies to compete with a company. Companies with a strong technology moat are typically valued at a premium to those that do not have a moat. HealthTech valuations on public markets today As of July 21, 2023, HealthTech valuations on public markets have been slashed. The average enterprise value (EV) to sales multiple for HealthTech companies is 4.8x, down from 5.6x in FY 2022. The average EV to EBITDA multiple is 11.0x, down from 12.5x in FY 2022. There are a number of factors that have contributed to the decline in HealthTech valuations, including: The overall economic slowdown, which has led to investors becoming more cautious about risk. The war in Ukraine, which has created uncertainty in the global markets. Rising interest rates, which have made it more expensive for companies to borrow money. Regulatory changes, such as the implementation of the Medicare Access and CHIP Reauthorisation Act (MACRA), which have made it more difficult for healthcare providers to make money. Future HealthTech valuations on public markets in 2024 It is difficult to predict the future, but there are a number of factors that suggest that HealthTech valuations on public markets could rebound in 2024. These factors include: The continued growth of the global healthcare market. The global healthcare market is expected to reach $10 trillion by 2024, providing a large addressable market for healthtech companies. The increasing adoption of digital health technologies. Digital health technologies are becoming increasingly popular, as they offer a number of benefits, such as improved efficiency, patient engagement, and outcomes. The growing focus on value-based care. Value-based care is a reimbursement model that rewards providers for delivering high-quality care at a lower cost. This model is likely to drive demand for HealthTech solutions that can help providers improve the quality and efficiency of care. Of course, there are also some risks that could weigh on HealthTech valuations in 2024. These risks include: The ongoing economic slowdown. The global economy is facing a number of challenges, which could lead to slower growth in the healthcare market. Regulatory changes. The healthcare industry is highly regulated, and any changes to regulations could impact the valuations of healthtech companies. Technological disruption. The healthcare industry is constantly evolving, and new technologies could emerge that disrupt the existing market. Overall, the future of HealthTech valuations on public markets is uncertain. However, there are a number of factors that suggest that valuations could rebound in 2024. Investors who are interested in HealthTech should carefully consider the risks and opportunities before investing in any HealthTech company. Nelson Advisors > Healthcare Technology M&A . Nelson Advisors specialise in mergers, acquisitions  &  partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions &  partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today !   https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025

Exec Summary: The HealthTech M&A landscape in 2025 is characterised by a mix of opportunity and caution. While innovative technologies continue to drive interest, financial discipline and strategic alignment are crucial for successful deals. The increase of distressed company M&A's is a large factor in the 2025 market. Outlook for 2025 Multiples are likely to hold steady at 4-6x revenue for most HealthTech firms, with upward pressure in AI, telehealth, and analytics if deal volume surges. Smaller, unprofitable startups may see compression (3-4x) unless they prove profitability or secure strategic buyers. Big Pharma’s looming patent cliffs could drive outlier deals (7-8x or more) for late-stage innovators, especially in biotech-adjacent HealthTech. Average revenue multiples The average revenue multiple for HealthTech companies in March 2025 is 4.8x. This is down from 6.5x in 2023 but still higher than the average revenue multiple for all technology companies, which is 3.5x. The higher revenue multiple for HealthTech companies reflects the fact that the healthcare market is growing rapidly and there is a lot of demand for innovative digital health solutions. The average revenue multiples for different types of HealthTech companies in March 2025 are: Telehealth companies: 5.6x to 4.8x Wellness companies: 4.4x to 3.3x Drug discovery companies: 7.8x to 5.4x Medical device companies: 5.6x to 4.5x Healthcare IT companies: 3.5x to 2.5x 10 Key Variables in HealthTech M&A valuation multiples today are: Stage of the company's development: Early-stage companies are typically valued at a lower multiple than more mature companies. Size of the company: Larger companies are typically valued at a higher multiple than smaller companies. Intellectual property portfolio: Companies with valuable intellectual property are typically valued at a higher multiple. Quality of the management team: A strong management team can add value to a company and may lead to a higher valuation. Revenue growth: This is one of the most important factors in determining the valuation of a healthtech company. Companies with strong revenue growth are typically valued at a premium to those with slower growth. Gross margin: Gross margin is a measure of a company's profitability. Companies with higher gross margins are typically valued at a premium to those with lower margins. Customer acquisition costs: Customer acquisition costs (CAC) are the costs associated with acquiring new customers. Companies with lower CACs are typically valued at a premium to those with higher CACs. Market share: Market share is a measure of a company's dominance in its industry. Companies with a large market share are typically valued at a premium to those with a smaller market share. Regulatory landscape: The regulatory landscape for healthtech is constantly evolving. Companies that operate in industries with a favourable regulatory environment are typically valued at a premium to those that operate in industries with a more challenging regulatory environment. Technology moat: A technology moat is a competitive advantage that makes it difficult for other companies to compete with a company. Companies with a strong technology moat are typically valued at a premium to those that do not have a moat. Why 4.8x to 6x multiples? Profitability Shift: Investors increasingly favour cash-flow-positive firms, tempering multiples from 2022 peaks but not crashing them. Growth Potential: HealthTech’s long-term outlook keeps it above non-health tech sectors. Market Sentiment: Early 2025’s economic thaw likely prevents further compression from 2023 lows. Nelson Advisors > Healthcare Technology M&A . Nelson Advisors specialise in mergers, acquisitions  &  partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions &  partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today !   https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025 HealthTech M&A valuation multiples HealthTech M&A valuation multiples are a set of metrics used to determine the value of a HealthTech company in an acquisition or merger. These multiples are typically based on financial metrics such as revenue, earnings, or users/subscribers, and can differ based on the company's stage of development, growth prospects, market position, and other relevant factors. Some of the most commonly used HealthTech M&A valuation multiples include: Enterprise value (EV) to sales: This multiple is the most common way to value healthtech companies. It is calculated by dividing the company's enterprise value (EV) by its trailing 12-month revenue. EV to EBITDA: This multiple is used to measure a company's profitability. It is calculated by dividing the company's EV by its earnings before interest, taxes, depreciation, and amortization (EBITDA). Price to earnings (P/E) ratio: This multiple is used to measure a company's valuation relative to its earnings. It is calculated by dividing the company's stock price by its earnings per share (EPS). Price to sales (P/S) ratio: This multiple is used to measure a company's valuation relative to its sales. It is calculated by dividing the company's stock price by its trailing 12-month revenue. The specific multiple that is used to value a HealthTech company will depend on a number of factors, including the company's stage of development, growth prospects, market position, and other relevant factors. However, the multiples listed above are a good starting point for understanding how HealthTech companies are valued in M&A transactions. It is important to note that valuation multiples are just one factor that is considered when valuing a healthtech company. Other factors, such as the company's management team, its intellectual property, and its strategic positioning, can also play a role in determining the company's valuation. Here are some of the recent trends in HealthTech M&A valuation multiples: Valuation multiples vary depending on the sub-sector of healthtech. For example, companies in the telehealth sector typically command higher valuation multiples than companies in the medical device sector. Valuation multiples are also affected by the stage of development of the company. Companies that are still in the early stages of development typically command lower valuation multiples than companies that are more mature. Valuation multiples have been increasing in recent years. This is due to a number of factors, including the growing demand for digital health solutions, the increasing investment in healthtech by venture capitalists, and the favorable regulatory environment for healthtech companies. What are the biggest trends likely to affect healthcare technology multiples in 2025? 1. AI Integration and Innovation What’s Happening: Artificial intelligence is transforming diagnostics, drug discovery, and patient care (e.g., predictive analytics, imaging AI). HealthTech firms with proprietary AI algorithms or scalable platforms are seeing heightened interest from buyers like pharma and hospitals. Impact on Multiples: Companies with proven AI solutions could see multiples rise to 6-8x revenue, above the sector average of 4.5-5x, as buyers pay premiums for innovation and future revenue potential. Firms lagging in AI adoption may face compression toward 3-4x. Why It Matters: AI’s ability to cut costs and improve outcomes aligns with healthcare’s biggest challenges, amplifying valuations for leaders. 2. Regulatory Evolution and Clarity What’s Happening: Regulatory bodies like the FDA are refining frameworks for digital health tools (e.g., Software as a Medical Device) and AI approvals. Post-2024 U.S. election, a pro-business administration might ease compliance burdens further. Impact on Multiples: Clear regulatory pathways boost confidence, lifting multiples by 0.5-1x for compliant firms (e.g., 5-6x vs. 4-5x). Uncertainty or delays, however, could cap multiples or deter deals, especially for early-stage companies. Why It Matters: Regulatory approval signals scalability and reduces risk, key drivers of M&A premiums. 3. Shift to Value-Based Care What’s Happening: Healthcare is moving from fee-for-service to value-based models, prioritizing outcomes over volume. HealthTech enabling this shift—think remote monitoring, population health analytics—gains traction with payers and providers. Impact on Multiples: Companies aligned with value-based care (e.g., chronic disease platforms) could see multiples climb to 5.5-7x, reflecting strategic fit. Non-aligned firms might stagnate at 3-4x. Why It Matters: Buyers like insurers and health systems pay more for tech that delivers measurable cost savings and patient outcomes, a growing priority in 2025. 4. Telehealth Maturation and Hybrid Models What’s Happening: Telehealth is evolving beyond standalone platforms into hybrid care models, integrating with in-person services (e.g., CVS Health’s primary care push). Growth has slowed from pandemic peaks, but adoption remains strong. Impact on Multiples: Mature telehealth firms with profitability or hybrid offerings sustain 5-7x multiples, while unprofitable pure-plays may drop to 4-5x. Strategic synergies with buyers could push outliers higher. Why It Matters: Telehealth’s stickiness and cost-efficiency keep it a premium subsector, though differentiation is now key. 5. Economic Recovery and Capital Availability What’s Happening: Falling interest rates in 2025 and $171 billion in pharma cash reserves (per late 2024 estimates) are thawing M&A markets. Private equity and strategic buyers are re-entering HealthTech with renewed vigour. Impact on Multiples: Increased deal competition could lift averages by 0.5x (e.g., 4.9x to 5.4x), especially for high-growth firms. Smaller or riskier targets might still see discounts if capital prioritizes proven winners. Why It Matters: Cheaper financing and cash-rich buyers fuel bidding wars, inflating valuations for desirable assets. 6. Data Monetisation and Interoperability What’s Happening: HealthTech firms that leverage patient data ethically (e.g., via analytics or interoperability with EHRs) are unlocking new revenue streams. Regulatory pressure for data sharing (e.g., 21st Century Cures Act) accelerates this trend. Impact on Multiples: Data-driven companies could command 5.5-7x multiples, as buyers value clean, actionable data. Firms with siloed or insecure data may lag at 4x or below. Why It Matters: Data is the backbone of modern healthcare, and tech enabling its flow or monetisation attracts premiums. 7. Aging Populations and Chronic Disease Focus What’s Happening: Global demographics—aging populations and rising chronic conditions—drive demand for HealthTech like wearables, remote monitoring, and personalised medicine. Impact on Multiples: Companies addressing these megatrends (e.g., diabetes management platforms) could see 6-7x multiples, outpacing the sector average. Less relevant players stay closer to 4-5x. Why It Matters: Long-term market tailwinds justify higher valuations for firms tackling unavoidable healthcare challenges. 8. Cybersecurity and Privacy Emphasis What’s Happening: High-profile healthcare data breaches and stricter privacy laws (e.g., GDPR, CCPA) are pushing HealthTech to prioritize security. Buyers scrutinise this closely. Impact on Multiples: Firms with robust cybersecurity might gain a 0.5-1x boost (e.g., 5-6x vs. 4-5x), while vulnerabilities could slash valuations or kill deals. Why It Matters: Trust and compliance are non-negotiable in healthcare, directly affecting buyer willingness to pay. Nelson Advisors > Healthcare Technology M&A . Nelson Advisors specialise in mergers, acquisitions  &  partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions &  partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today !   https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025

OpenAI's Acquisition of io could reshape Healthcare's Digital Future OpenAI's Acquisition of io could reshape Healthcare's Digital Future OpenAI’s $6.5 billion acquisition of io, the AI hardware startup founded by former Apple design chief Jony Ive, marks a significant step toward integrating advanced AI with consumer hardware, potentially reshaping healthcare’s digital future. While no specific healthcare-focused device has been announced, the convergence of OpenAI’s AI expertise and io’s design-driven hardware innovation could have profound implications for healthcare through novel devices, enhanced AI applications, and streamlined clinical workflows. Below, the Nelson Advisors team explore how this acquisition could influence healthcare’s digital landscape, drawing on OpenAI’s existing healthcare efforts and the speculative potential of AI-powered hardware. 1. Potential for AI-Powered Healthcare Devices The acquisition of io signals OpenAI’s ambition to create a “new generation of AI-powered computers” that move beyond traditional screens, potentially including wearables, headphones, or camera-equipped devices designed to be unobtrusive and contextually aware. In healthcare, such devices could transform patient monitoring, diagnostics, and care delivery by: Continuous Health Monitoring: A compact, AI-driven wearable could use multimodal AI (integrating voice, image, and sensor data) to monitor vital signs, detect early health issues, or provide real-time feedback. For example, a device could analyse heart rate, movement, or even visual cues like skin changes to alert users to potential health risks, such as arrhythmias or skin conditions. Personalised Health Assistants: Inspired by the “Her” movie concept, a screen less AI companion could act as a 24/7 health coach, offering personalised guidance based on user data (e.g., sleep patterns, activity levels) similar to OpenAI’s partnership with WHOOP for the WHOOP Coach. It could answer questions like, “How can I improve my sleep?” or suggest tailored exercise plans. Point-of-Care Diagnostics: Devices with cameras and AI could enable at-home diagnostics, such as analyzing medical images (e.g., skin lesions) or guiding users through symptom assessments, akin to Babylon Health’s AI-driven symptom checkers. This could democratise access to healthcare, especially in underserved regions. Jony Ive’s design philosophy, known for creating intuitive and user-friendly products like the iPhone, could ensure these devices are seamless and appealing, encouraging adoption by patients and clinicians alike. 2. Enhancing OpenAI’s Healthcare AI with Hardware Integration OpenAI’s release of HealthBench, an open-source benchmark for evaluating large language models (LLMs) in healthcare, demonstrates its commitment to safe and effective AI in clinical settings. The io acquisition could amplify this by embedding HealthBench-calibrated AI into physical devices, enabling: Real-Time Clinical Support: A device running HealthBench-optimized LLMs could assist clinicians at the point of care, providing real-time diagnostic suggestions or summarizing patient records. For instance, a wearable or handheld device could transcribe doctor-patient conversations, generate visit notes (as seen in OpenAI’s partnership with Summer Health), or suggest treatment plans based on EHR data. Patient Empowerment: Devices could deliver HealthBench-evaluated AI outputs directly to patients, translating complex medical information into plain language or providing personalized care plans, as Color Health’s AI-powered cancer co-pilot does. This could improve health literacy and self-management. Ethical AI Deployment: HealthBench emphasises safety, trustworthiness, and real-world applicability. Hardware designed by io could incorporate these principles, ensuring AI outputs are secure, private, and aligned with healthcare standards, addressing concerns about AI accuracy and hallucinations (e.g., issues with OpenAI’s Whisper in medical transcriptions). 3. Streamlining Healthcare Workflows The integration of AI hardware could address administrative burdens, a major pain point in healthcare. OpenAI’s partnerships, such as with Iodine Software for revenue cycle management and UTHealth Houston for medical training algorithms, show its focus on operational efficiency. Potential impacts include: Reducing Clinician Burnout: AI-powered devices could automate tasks like clinical documentation or scheduling, as seen with Meta’s Llama model reducing manual annotations by 70-80%. An io designed device could make these interactions more intuitive, allowing clinicians to focus on patient care. Optimising Resource Allocation: Devices equipped with predictive analytics could help hospitals manage resources, similar to Northwestern Medicine’s use of AI for scheduling and resource tracking. For example, a device could provide real-time data on patient flow or equipment needs. Enhancing Telemedicine: Screen less AI devices could enable seamless virtual consultations, using voice or environmental data to facilitate remote care, building on platforms like Sensely’s AI virtual health assistants. 4. Broader Implications for Healthcare’s Digital Ecosystem The io acquisition positions OpenAI to compete with tech giants like Apple, Google, and Meta, all of which are advancing AI in healthcare. This could accelerate innovation and create a more interconnected digital health ecosystem: Competition and Innovation: Apple’s struggles with generative AI and its delayed “Apple Intelligence” rollout highlight OpenAI’s opportunity to lead in AI-native devices. A successful OpenAI-io device could push competitors to innovate faster, potentially leading to advanced wearables or diagnostic tools. Interoperability: OpenAI’s focus on cross-platform AI integration (e.g., with SAP, Microsoft, or Salesforce) suggests future devices could interface with existing healthcare systems, improving data sharing and care coordination. Global Health Impact: With 4.5 billion people lacking access to essential healthcare, AI devices could bridge gaps, especially in low-resource settings, by providing affordable diagnostics or virtual care, aligning with the World Economic Forum’s vision for AI to support universal health coverage. 5. Challenges and Considerations Despite the potential, challenges remain: Privacy and Security: Healthcare devices must comply with strict regulations like HIPAA. OpenAI will need to ensure robust data security, especially for always-on devices with cameras or microphones. Adoption Barriers: Only 29% of UK survey respondents trust AI for basic health advice, indicating public skepticism. User-friendly design from io could help, but building trust will require rigorous testing and transparency. Regulatory Hurdles: Medical devices face stringent FDA or equivalent approvals, which could delay deployment. OpenAI’s lack of experience in hardware regulation may pose challenges. Speculative Nature: No specific healthcare device has been confirmed, and the 2026 debut timeline means impacts are speculative. The focus on “screen less” devices may prioritise general consumer use over healthcare-specific applications. OpenAI’s acquisition of io could reshape healthcare’s digital future by combining cutting-edge AI with innovative hardware, potentially leading to intuitive devices for monitoring, diagnostics, and clinical support. While HealthBench and existing partnerships lay the groundwork for AI in healthcare, io’s design expertise could make these tools more accessible and impactful. However, success depends on overcoming privacy, regulatory, and adoption challenges. The full impact will likely emerge post-2026, as OpenAI unveils its first devices. Nelson Advisors > Healthcare Technology M&A . Nelson Advisors specialise in mergers, acquisitions  &  partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions &  partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today !   https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025 Nelson Advisors specialise in mergers, acquisitions  &  partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America

Nelson Advisors partner Lloyd Price has been invited to Judge the HealthInvestor 2025 Awards for the second year in a row and third time overall for the Nexus Media Group. The Awards evening and presentations will take place on the 4th June 2025 at the Grosvenor House Hotel in London. https://healthinvestorawards.com The Awards are hosted by Nexus Media Group, a leading B2B publishing and events company for the health, social care, seniors housing, education, early years and property sectors. Nexus Media Group is a publishing and events company, which focuses on the health, education, early-years and property sectors. Our range of established media titles and sector-leading events provide market intelligence and business connections, underpinned by a long-standing commitment to editorial excellence. The Awards are attended by over 1,200 of the sector’s leading figures. Attendees are typically advisors, investors or operators within the independent healthcare sector but the Awards are open for anyone to attend. "Recognising achievement in the business of healthcare > For nearly 20 years Nexus Media Group have been celebrating the very best in health and social care, across categories including Advisory & Finance, Clinical Services, Property and more." Healthcare Technology Provider of the Year > Finalists CLEO Systems Healthcode ImproveWell Lottie Neural Pathways Pharmacierge PharmBot AI Radar Healthcare Staffscanner TestCard Social Care Technology Provider of the Year > Finalists Aspirico Breis CHMS CareBrain CoolCare Earzz PASS by everyLIFE Person Centred Software PredicAire Symphony Sound All the Award Finalists can be found here - https://healthinvestorawards.com/finalists-2025/ Nexus Media Group The Awards are hosted by Nexus Media Group, a leading B2B publishing and events company for the health, social care, seniors housing, education, early years and property sectors. Nexus Media Group is a publishing and events company, which focuses on the health, education, early-years and property sectors. Our range of established media titles and sector-leading events provide market intelligence and business connections, underpinned by a long-standing commitment to editorial excellence.   Established in 2004, our London-based team of journalists and sector experts provide insight and introductions to complex marketplaces. Nelson Advisors > Healthcare Technology M&A . Nelson Advisors specialise in mergers, acquisitions  &  partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions &  partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today !   https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025

UK’s HealthTech Index 2025: Key Points from the Startup Coalition’s Inaugural HealthTech Report The Startup Coalition UK’s inaugural HealthTech Index, using data from Beauhurst (2025), highlights the following key points about the UK’s health tech sector: Sector Value and Funding: UK health tech startups were valued at £32 billion by the end of 2024, raising a combined £27.4 billion in capital, with an average of £9.6 million per company. Additionally, £865 million in grant funding was secured. Employment and Growth: The sector employs nearly 30,000 people, with 168 firms achieving exits compared to only 61 failures, indicating a robust and dynamic ecosystem. Subsector Performance: Biopharmaceuticals: The most valuable and populous sub-sector, with 276 startups raising £11.9 billion, accounting for 36% of the sector’s total value. Notable deals include Verdiva Bio’s £333.5 million Series A in 2025 and Ottimo Pharma’s £104 million Series A. Biotechnology: 138 startups raised £3.3 billion. Digital Health: 95 firms secured £2.8 billion and employ over 5,000 people, representing 17% of the sector’s workforce. AI and Data Analytics: Surprisingly, this segment raised only £1 billion with a valuation of £1.4 billion, lagging behind other tech sectors where AI typically dominates. Investment Trends: The sector saw a record £795 million raised in 2024, driven by the post-COVID acceleration of digital healthcare services like virtual GP appointments and remote monitoring. Policy Recommendations: The report calls for NHS procurement reforms to better integrate innovative solutions, scaling up public sector accelerators, and supporting spinouts to sustain growth. HealthTech Definition and Scope: HealthTech encompasses technologies like software, apps, and wearables focused on preventative care and personal health management, distinct from medtech, which targets in-hospital diagnostics and devices requiring stricter regulatory approval. These insights reflect a thriving yet policy-constrained sector, with biopharma leading in funding and digital health excelling in job creation. https://api.startupcoalition.io/u/2025/05/HealthTech-Index-2025_FINAL.pdf Key statistics from the startup coalition UK’s inaugural HealthTech index using data from Beauhurst report 2025 The Startup Coalition UK’s inaugural HealthTech Index, based on Beauhurst’s 2025 data, provides the following key statistics about the UK’s health tech sector: Total Valuation: £32 billion by the end of 2024. Capital Raised: £27.4 billion in total equity funding, with an average of £9.6 million per company. Grant Funding: £865 million secured across the sector. Employment: Nearly 30,000 people employed. Exits vs. Failures: 168 firms achieved exits, compared to 61 failures. Investment in 2024: A record £795 million raised. Subsector Breakdown: Biopharmaceuticals: 276 startups raised £11.9 billion, accounting for 36% of the sector’s total value. Biotechnology: 138 startups raised £3.3 billion. Digital Health: 95 firms raised £2.8 billion, employing over 5,000 people (17% of the sector’s workforce). AI and Data Analytics: Raised £1 billion, with a valuation of £1.4 billion. These figures highlight a robust sector with strong growth in biopharma and digital health, though AI lags behind expectations. Exits and Failures The Startup Coalition UK’s inaugural HealthTech Index 2025, based on Beauhurst data, provides the following key statistics regarding failures and exits in the UK’s health tech sector: Exits: 168 health tech firms achieved exits by the end of 2024. This includes events such as acquisitions, initial public offerings (IPOs), or other forms of successful market exits, indicating a mature and dynamic ecosystem with significant investor and market interest. Failures: 61 firms in the sector failed, reflecting a relatively low failure rate compared to the number of exits. This suggests resilience in the health tech sector, with successful companies outnumbering those that did not survive. Context and Significance: The ratio of 168 exits to 61 failures underscores the sector’s robustness, with nearly three times as many companies achieving successful outcomes as those that ceased operations. The high number of exits aligns with the sector’s strong funding environment, having raised £27.4 billion in equity and £865 million in grants, with a total valuation of £32 billion. The low failure rate may reflect the sector’s ability to attract sustained investment, particularly in high-value sub-sectors like biopharmaceuticals (£11.9 billion raised) and digital health (£2.8 billion raised), which support company longevity and scalability. The report calls for 3 main changes in procurement, innovation and spinouts: NHS procurement reform: A reformed, structured approach to NHS procurement is crucial to unlock the full potential of the UK’s HealthTech startup ecosystem and facilitate the adoption of innovative solutions. Innovation pathways: Scaling existing NHS-backed accelerator programmes and enhancing their operational efficiency and coordination will provide better support for startups navigating the healthcare landscape. University spinouts: To encourage the growth of university spinouts into substantial national businesses, the Government should reassess its guidance to university technology transfer offices, advocating for a lower average equity stake to foster founder incentives and future investment. https://api.startupcoalition.io/u/2025/05/HealthTech-Index-2025_FINAL.pdf Nelson Advisors > Healthcare Technology M&A . Nelson Advisors specialise in mergers, acquisitions  &  partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions &  partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today !   https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025 Nelson Advisors specialise in mergers, acquisitions  &  partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America

AI Scribes and Ambient AI: Key Differences for Healthcare Providers Overview of AI Scribes and Ambient Artificial Intelligence AI Scribes and Ambient Artificial Intelligence (AI) are transformative technologies in healthcare designed to streamline clinical documentation, reduce administrative burdens, and enhance patient-provider interactions. These tools leverage advanced AI, including large language models (LLMs), speech recognition, and natural language processing (NLP), to automate the process of capturing and documenting patient encounters. Below is a comprehensive overview of AI scribes and ambient AI, including their functionality, benefits, challenges, and applications. What Are AI Scribes and Ambient AI? AI Scribes: AI scribes, also referred to as automated medical scribes, digital scribes, virtual scribes, or ambient AI scribes, are tools that transcribe and summarize medical conversations, such as patient consultations or dictated notes. They use AI technologies to generate structured clinical notes, reducing the time clinicians spend on documentation. Unlike traditional dictation tools or human scribes, AI scribes operate autonomously or with minimal human oversight, often integrating directly with electronic health record (EHR) systems. Ambient AI: Ambient AI is a subset of AI that operates proactively and intuitively in the background, responding to environmental cues (e.g., conversations) without requiring direct user input. In healthcare, ambient AI refers to technologies that "listen" to patient-provider interactions, transcribe them in real-time, and generate clinical documentation or other outputs (e.g., coding suggestions, patient summaries). These systems are designed to be unobtrusive, enhancing workflow efficiency while maintaining focus on patient care. Key Components: Automatic Speech Recognition (ASR): Converts spoken conversations into text transcripts. Natural Language Processing (NLP): Analyses transcripts to extract relevant clinical information and generate structured notes, such as SOAP (Subjective, Objective, Assessment, Plan) notes. Large Language Models (LLMs): Power the synthesis of transcripts into concise, accurate, and specialty-specific clinical documentation. Examples include models like GPT-4. EHR Integration: Many AI scribes integrate with EHR systems to directly input notes, codes, or orders, streamlining workflows. How AI Scribes and Ambient AI Work Capture: A secure microphone (often on a smartphone or dedicated device) listens to patient-provider conversations or clinician dictations in real-time. Audio is typically not stored to ensure privacy compliance (e.g., HIPAA). Transcription: ASR technology converts the audio into text transcripts. Synthesis: NLP and LLMs process the transcript to identify key clinical details, filter out irrelevant information (e.g., small talk), and generate structured clinical notes, coding suggestions, or patient summaries. Review and Integration: Clinicians review and edit the AI-generated notes before finalizing them in the EHR. Some systems also automate tasks like coding (e.g., CPT, ICD-10), referrals, or patient follow-up instructions. Example Workflow: A physician conducts a patient visit, and the ambient AI scribe listens via a smartphone app. The system transcribes the conversation, filters out non-clinical content (e.g., discussions about pets), and generates a SOAP note within minutes. The physician reviews and edits the note, then uploads it to the EHR with a single click. Applications and Use Cases AI scribes and ambient AI are used across various healthcare settings and specialties, including: Primary Care: Automates documentation for routine check-ups, allowing physicians to focus on patient interaction. Specialty Care: Tailored for complex fields like oncology, psychiatry, or orthopaedics, where notes require specific terminology or longitudinal data. For example, DeepScribe’s oncology-specific AI handles detailed cancer care documentation. Emergency Medicine: Supports high-volume settings where rapid, accurate documentation is critical. Mental Health: Tools like Mentalyc generate intake and progress notes for psychotherapy, capturing nuanced patient histories. Home Health: Tools like Andy assist with OASIS assessments, improving accuracy in home health visits. Additional Features: Coding and Compliance: Automates CPT and ICD-10 coding, reducing billing errors. Patient Summaries: Generates after-visit summaries (AVS) to reduce follow-up inquiries. Referrals and Orders: Automates referral letters and lab orders, streamlining workflows. Benefits Reduced Documentation Burden: Studies show AI scribes save physicians significant time, with some reporting an average of 1 hour per day saved on documentation. A Stanford pilot found a 24.42-point reduction in task load and a 1.94-point reduction in burnout scores. Median time per note reduced by 0.57 minutes, and daily documentation time decreased by 6.89 minutes in one study. Improved Patient-Provider Interaction: By automating note-taking, clinicians can maintain eye contact and engage more fully with patients, enhancing the patient experience and care quality. Enhanced Efficiency: AI scribes streamline workflows by integrating with EHRs, automating coding, and reducing after-hours clerical work. Adoption rates are high, with 20–80% of clinicians using the technology where available, and some organisations reporting 90% uptake in primary care. Cost-Effectiveness: AI scribes cost approximately $100/month per user compared to $2,800/month for human scribes, offering significant savings. Small practices and large health systems alike benefit from scalable solutions. High Accuracy: Tools like DeepScribe claim 59% higher accuracy than GPT-4 alone, with some achieving 90–98% accuracy in generating structured notes. Challenges and Limitations Accuracy Issues: AI scribes may struggle with complex interactions, such as case conferences or multilingual conversations, and can produce errors like misattributing speakers or omitting critical details. LLMs may generate “hallucinations” (convincing but incorrect information), requiring careful clinician review. Privacy and Security: Compliance with HIPAA and other regulations (e.g., FOIPPA in Canada) is critical. Some systems use zero-knowledge encryption, while others may send data to external servers, raising privacy concerns. Patient consent is required before recording interactions, and secure data handling is essential. Integration Challenges: Seamless EHR integration is necessary to avoid additional clinician workload. Compatibility issues can hinder adoption. Some systems require deeper EHR integration for advanced features like order entry or flowsheet updates. Adoption Barriers: Clinicians who have optimised manual documentation processes may see less benefit and resist adoption. Training and customisation are needed to align notes with individual clinician styles or specialty needs. Cost and Scalability: While cheaper than human scribes, implementation and maintenance costs can be significant for smaller practices. Ongoing updates and training requirements add to expenses. Ethical and Legal Concerns: Physicians remain accountable for AI-generated errors, necessitating thorough review. Bias in algorithms or misuse of patient data for training raises ethical questions Ambient AI vs AI Scribe: What’s the Difference? Ambient AI vs AI Scribe: What’s the Difference? While both "Ambient AI" and "AI Scribes" aim to streamline documentation and improve efficiency in healthcare, they differ significantly in their scope, integration, and the breadth of support they offer: AI Scribes (or Digital/Virtual Scribes) Core Function: Primarily focuses on transcribing spoken conversations between a healthcare provider and a patient during a consultation. Their main output is a draft clinical note. Scope: Typically acts as a point solution or a standalone application. Their primary purpose is to automate the note-taking aspect of a patient encounter. Integration: May have limited or less deep integration with Electronic Health Records (EHRs). The generated notes might need to be manually reviewed, edited, and then copied or imported into the EHR. Workflow Support: Primarily supports the "during visit" phase by capturing the spoken dialogue. They largely reduce the need for manual typing during the consultation. Output: Generates a draft clinical note (e.g., SOAP note, general consultation summary) for the clinician to review and finalise. Analogy: Think of an AI Scribe as a highly advanced, automated stenographer for medical consultations. Ambient AI in Healthcare Core Function: Encompasses a broader, more seamless and integrated AI technology that not only handles documentation from conversations but also proactively assists with various aspects of the clinical workflow. It operates in the background, often without explicit commands. Scope: Designed to support the entire patient journey and clinical workflow – before, during, and after the visit.It aims to create an "intelligent environment" within the care setting. Integration: Characterised by deep integration with EHR systems and other clinical tools. This allows Ambient AI to pull relevant patient data pre-visit, document seamlessly during the visit, and automate post-visit tasks directly within the existing clinical ecosystem. Workflow Support: Provides comprehensive support, including: Pre-visit: Surfacing relevant patient history, lab results, or imaging prior to the encounter. During visit: Unobtrusively capturing conversations and generating documentation, but also potentially offering real-time clinical decision support. Post-visit: Automating tasks like generating referral letters, ordering tests, populating billing codes, sending follow-up instructions to patients, and updating various parts of the patient's record. Output: Beyond just draft notes, it can generate a range of outputs, including summaries, letters, forms, and suggestions for follow-up actions, all integrated into the patient's record. Analogy: Think of Ambient AI as a comprehensive, intelligent assistant that anticipates needs and performs tasks across the entire clinical encounter, blending seamlessly into the background. Key Differences Summarised Feature AI Scribe Ambient AI Scope Narrow: Primarily documentation Broad: Documentation + workflow automation Integration Point solution, less deep EHR integration Deeply integrated with EHRs and clinical systems Workflow Phase Primarily "during visit" "Before, during, and after" visit support Interaction Focus on transcribing spoken word Unobtrusive, operates in the background, proactive Output Range Draft clinical notes Notes, referrals, orders, billing codes, follow-ups In essence, an AI Scribe is a component or a specific application within the broader concept of Ambient AI. Many technologies that started as "AI Scribes" are evolving to offer more "ambient" capabilities, blurring the lines as they integrate more deeply into the clinical workflow. The goal of both is to free healthcare providers from administrative burdens, allowing them to focus more on patient care . Nelson Advisors > Healthcare Technology M&A . Nelson Advisors specialise in mergers, acquisitions  &  partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions &  partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today !   https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025